SANISURE LIMITED
Company number 01449832 · Monitor this company
This analysis was written by an AI from the company's public filings. It may contain errors or omissions and is not financial or professional advice.
Credit Analysis: SANISURE LIMITED (01449832)
1. Credit Opinion: CONDITIONAL
Reasoning: The credit opinion must be conditional due to material data limitations. As an audit-exempt subsidiary filing abbreviated accounts, SANISURE LIMITED's standalone financial position cannot be meaningfully assessed from public filings. The company benefits from several positive structural factors—long trading history (45+ years), operation in a defensive medical/pharmaceutical sector, and apparent group backing—however, the dependency on parent entity support and absence of standalone financial performance data creates uncertainty regarding independent debt-servicing capacity. Any credit facility should be contingent upon receipt of group guarantee and consolidated financial statements.
2. Financial Strength
Limited Assessable Data: As an audit-exempt subsidiary, the company files materially reduced disclosures. No balance sheet, profit & loss, or cash flow data is available for analysis.
Structural Observations: - Share Capital: £50,000 — modest, though likely not reflective of actual capital employed given group structure - Ownership: Controlled by two acquisition vehicles (Q Uk Acquisition Company Limited and Sanisure Acquisition Company Limited), both holding >75% of shares and voting rights with rights to appoint/remove directors. This is a wholly-owned subsidiary within a larger group. - Group Support Indicator: The recent rebrand from SILICONE-ALTIMEX LIMITED to SANISURE LIMITED (September 2022) aligns with the PSC naming convention, suggesting integration into the Sanisure group structure. This typically implies parent company investment and strategic commitment.
Assessment: Standalone balance sheet strength cannot be determined. Group-level financial statements would be required to assess true leverage, asset quality, and equity position.
3. Cash Flow Assessment
No Quantitative Data Available: Working capital position, cash reserves, trade debtor/creditor ratios, and operating cash flows cannot be assessed from available filings.
Qualitative Considerations: - Sector Dynamics: Manufacturing of rubber/elastomeric products for medical devices and bio-pharmaceutical applications typically generates recurring revenue from regulated, essential supply chains. This sector demonstrated resilience through recent economic disruptions. - Group Dependency: Cash flow dependency on parent company intercompany arrangements is highly likely. Working capital may be managed centrally within the group. - Operational Longevity: 45 years of continuous operation suggests sustainable cash generation, though historical performance under previous ownership structures may not be indicative of future performance under the Sanisure group.
Assessment: Cash flow viability is inseparable from group-level performance. Standalone cash flow analysis is not possible without management accounts or group consolidated statements.
4. Monitoring Points
| Metric | Rationale |
|---|---|
| Group Consolidated Financials | Essential for understanding true financial position and debt-servicing capacity |
| Parent Company Guarantee | Critical for any facility extended to the subsidiary entity |
| Intercompany Balances | Determine extent of upstream/downstream cash sweeps or debt |
| Filing Timeliness | Continued compliance with Companies House obligations |
| Group Ownership Changes | Any change in PSC structure could alter support assumptions |
| Sector-Specific Regulation | Medical device manufacturing carries regulatory risk (MDR compliance) |
| Operational Performance | Request management accounts showing revenue trajectory, EBITDA margins, and capex requirements |
| Director Appointments/Resignations | Current board includes multiple nationalities suggesting group-appointed oversight; monitor for changes |
Key Risk: The primary credit risk is information asymmetry. The company's standalone creditworthiness is opaque due to subsidiary status, and reliance on implied group support—without sight of group financials or formal guarantee—represents unacceptable uncertainty for unsecured lending.
Mitigating Factor: The medical/pharmaceutical supply sector carries defensive characteristics, and the group's investment in rebranding suggests strategic commitment rather than asset-stripping intent.